DDInter1607 DDInter1840
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Ritonavir {u} (Compound) causes {v} (Side Effect) Weight decreased
Weight decreased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Ritonavir {u} (Compound) resembles {v} (Compound) Carfilzomib
Carfilzomib {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Ritonavir (Compound) causes Weight decreased (Side Effect) and Weight decreased (Side Effect) is caused by Trabectedin (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Ritonavir (Compound) resembles Carfilzomib (Compound) and Carfilzomib (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Trabectedin (Compound)